<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective was to retrospectively study the efficacy and safety of levetiracetam (keppra) as an add-on treatment of pharmacoresistant forms of <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> in children </plain></SENT>
<SENT sid="1" pm="."><plain>We have analyzed medical histories of 192 patients with pharmacoresistant <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> admitted to a neurological department of the Research and Treatment Center of Children's Medical Care over the period of 2008-2011 </plain></SENT>
<SENT sid="2" pm="."><plain>The patient's age varied in the range from 6 months to 19 years (mean age 5.7 years) </plain></SENT>
<SENT sid="3" pm="."><plain>The results of the study revealed the high efficacy of levetiracetam as an add-on treatment of pharmacoresistant <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> in children </plain></SENT>
<SENT sid="4" pm="."><plain>The efficacy of &gt; 50%, including patients in the remission, was found in 60.2%, the remission of more than 6 months was observed in 20.3% of patients </plain></SENT>
<SENT sid="5" pm="."><plain>The efficacy of levetiracetam was higher in the treatment of the following variants of pharmacoresistant <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e>: <z:hpo ids='HP_0001250'>seizures</z:hpo> caused by brain defects (the efficacy of &gt; 50% was seen in 66.7% of patients), atypical <z:e sem="disease" ids="C0376532" disease_type="Disease or Syndrome" abbrv="BECTS">rolandic epilepsy</z:e> (the efficacy of &gt; 50% was seen in 100% of patients) </plain></SENT>
<SENT sid="6" pm="."><plain>The efficacy of levetiracetam was not correlated with the priority of prescription of the drug that might be explained by the unique mechanism of the action of this <z:chebi fb="0" ids="35623">anticonvulsant</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Levetiracetam is well tolerated in the children age </plain></SENT>
<SENT sid="8" pm="."><plain>Side-effects that were not life threatening were noted only in 6.2% of patients and the retention rate was 75.5% </plain></SENT>
<SENT sid="9" pm="."><plain>The aggravation of <z:hpo ids='HP_0001250'>seizures</z:hpo> and <z:hpo ids='HP_0002353'>EEG abnormalities</z:hpo>, regardless of the <z:e sem="disease" ids="C0014544" disease_type="Disease or Syndrome" abbrv="">epilepsy</z:e> form, type of <z:hpo ids='HP_0001250'>seizure</z:hpo>, drug dose or the combination of <z:chebi fb="0" ids="35623">anticonvulsants</z:chebi> were seen in 5.7% of patients </plain></SENT>
</text></document>